# SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Source: https://onco.cc/trials/nct07131319/  
OnCo record `nct07131319` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting.

## Summary

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC is a phase 2/3, interventional study registered as NCT07131319 by Second Affiliated Hospital of Nanchang University, with a registry enrolment figure of 30 participants, started 2025-04-21 and due to reach its primary completion in 2028-10-31. Interventions recorded: Spatially Fractionated Radiotherapy (SFRT); Tislelizumab, Carboplatin, Pemetrexed; Tislelizumab, paclitaxel, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Surgical resection rate. Lung eligibility wording from the registry: "* The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07131319
- Phase: 2/3
- Setting: Spatially Fractionated Radiotherapy (SFRT) Synchronized With Tislelizumab Plus Platinum-based Dual-agent Chemotherapy for Induction Treatment of Initially Unresectable Stage III Non-small Cell Lung Cancer: A Clinical Study
- Sponsor: Second Affiliated Hospital of Nanchang University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07131319: https://clinicaltrials.gov/study/NCT07131319

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07131319.json